|
PPARGC1A
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mechanistically, we confirmed that ST protected against NAFLD through activation of PGC-1α and its downstream signaling pathways as shown by the attenuated hepatic adipogenesis and lipid accumulation, increased hepatic fatty acid oxidation, regulated plasma lipid parameters, and increased energy expenditure and metabolic function in fat and muscle.
|
31843573 |
2020 |
|
PPARGC1A
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Abbreviations: WAT: white adipose tissue; PPAR: Peroxisome proliferators-activated receptor; RXR: retinoid X receptors; mTORC1: mechanistic target of rapamycin complex 1; PPRE: PPAR-responsive regulatory elements; NAFLD: nonalcoholic fatty liver disease; LPL: lipoprotein lipase; FGF21: fibroblast growth factor 21; BAT: brown adipose tissue; UCP1: uncoupling protein 1; LPC(16:0): 1-palmitoyl lysophosphatidylcholine; C/EBP: CCAAT-enhancer binding proteins; STAT5A: signal transduction and activator of transcription 5A; APO apolipoptotein; CBP: cAMP response element-binding protein-binding protein; PGC1A: PPARγ coactivator protein 1a; HFD: high-fat diet; TG: triglyceride; VLDL: very low density lipoprotein; HDL: high density lipoprotein.
|
30572788 |
2019 |
|
PPARGC1A
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, BP reversed the decline of PGC-1α expression induced by NAFLD, while SIRT1 silencing significantly suppressed the effects of BP on PGC-1α.
|
30785444 |
2019 |
|
PPARGC1A
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We investigated whether reduced expression of PGC1A contributes to development of NAFLD using mouse models, primary hepatocytes, and human cell lines.
|
27658772 |
2017 |
|
PPARGC1A
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The rs2454206" genes_norm="54790">p.Ile1762Val substitution (TET2-rs2454206) was associated with liver PPARGC1A-methylation and transcriptional levels, and Type 2 diabetes.Our results suggest that 5-hmC might be involved in the pathogenesis of NAFLD by regulating liver mitochondrial biogenesis and PPARGC1A expression.
|
26356709 |
2015 |
|
PPARGC1A
|
0.100 |
Biomarker
|
disease |
BEFREE |
TXNIP mediates hepatic lipogenesis via PRMT1 and PGC-1α regulation and inflammation in vitro and in vivo, implying that targeting TXNIP and PRMT1 is a potential therapeutic approach for treatment of NAFLD.
|
25003952 |
2014 |
|
PPARGC1A
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although clinical evidence suggests that Gly482Ser polymorphism of PGC-1α is associated with an increased incidence of nonalcoholic fatty liver disease, a direct role for Gly482Ser mutation in altering PGC-1α actions on hepatocyte fat deposition remains to be explored.
|
23602251 |
2013 |
|
PPARGC1A
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the independent influence of the PPARGC1A rs8192678 risk A allele on pediatric NAFLD after control for the effect of the PNPLA3 rs738409 polymorphism.
|
23269818 |
2013 |
|
PPARGC1A
|
0.100 |
Biomarker
|
disease |
BEFREE |
We specifically examined whether fatty liver and IR are modified by hepatic DNA methylation of the peroxisome proliferator-activated receptor γ coactivator 1α (PPARGC1A) and mitochondrial transcription factor A (TFAM) promoters, and also evaluated whether liver mitochondrial DNA (mtDNA) content is associated with NAFLD and IR.
|
20890895 |
2010 |
|
PPARGC1A
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This finding suggested that PPARGC1A polymorphism and lower expression of PPARGC1A mRNA in the liver are an important genetic contribution to etiology of NAFLD.
|
18588668 |
2008 |
|
PPARGC1A
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to investigate the genetic polymorphisms of PPAR-gamma and PGC-1alpha in Chinese people and their influence on plasma adiponectin levels and non-alcoholic fatty liver disease (NAFLD) susceptibility.
|
17999673 |
2008 |
|
PPARGC1A
|
0.100 |
Biomarker
|
disease |
BEFREE |
PPARgamma coactivator 1 (PGC1) was significantly lower in subjects with NAFL than in those without.
|
17704301 |
2007 |